Dr. Lloyd Klickstein

Dr. Lloyd Klickstein was appointed as Scientific Advisor for Immunology at Harbour BioMed in June 2026. He brings more than two decades of leadership experience spanning biopharmaceutical innovation, translational research, and clinical medicine, with expertise in advancing novel antibody therapeutics from discovery through clinical development.

Dr. Klickstein holds a B.S. from Tufts University and an M.D. and Ph.D. from Harvard University. He completed post-graduate clinical training in Internal Medicine, Rheumatology & Immunology at Brigham and Women's Hospital (BWH) and a post-doctoral research fellowship at the Center for Blood Research in Boston.

Career History

• Chief Executive Officer, Koslapp Therapeutics (current role)
• Co-founder and multiple executive leadership positions at Versanis Bio (acquired by Eli Lilly and Company in August 2023)
• Chief Innovation Officer at Adicet Bio
• Chief Scientific Officer of resTORbio (Adicet's predecessor company)
• Global Head of Translational Medicine for the New Indication Discovery Unit and the Exploratory Disease Area at Novartis Institutes for Biomedical Research, where he led teams that developed programs in nonalcoholic steatohepatitis, gene therapy for hearing loss, gene editing for sickle cell anemia, and TORC1 inhibitors for diseases of aging
• Physician-scientist at Brigham and Women's Hospital, where he directed an NIH-funded basic research laboratory and maintained an active clinical practice in the Arthritis Center

What Dr. Klickstein could bring to his role as Scientific Advisor for Immunology at Harbour BioMed: His track record of translating basic immunology research into clinical therapeutic candidates, combined with expertise in identifying novel drug targets and deep understanding of rheumatologic and immunologic diseases, positions him to accelerate Harbour BioMed's antibody discovery pipeline and help advance programs addressing unmet needs in immunological diseases.

This is an automatically generated Light profile created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.